FP
STAB

Financial Perspectives’s Statera Biopharma, Inc. Common Stock STAB Stock Holding History

Financial Perspectives’s Portfolio STAB Stock Details STAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-8,941
Closed -$1.16K – 708
2022
Q3 		$1.16K Hold
8,941
– – ﹤0.01% 621
2022
Q2 		$2.55K Hold
8,941
– – ﹤0.01% 575
2022
Q1 		$2.82K Buy
8,941
+6,436
+257% +$6.88K ﹤0.01% 576
2021
Q4 		$5.76K Buy
+2,505
New +$7.39K ﹤0.01% 496

Other funds holding STAB

Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TSS
Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Cambridge Investment Research Advisors
Cambridge Investment Research Advisors Fairfield, Iowa $38.8B AUM 21.88% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Financial Perspectives's STAB Position: Q4 2022 in Review

Financial Perspectives sold out of Statera Biopharma, Inc. Common Stock (STAB) in Q4 2022, closing a stake of 8,941 shares — an estimated $1.16K sold.

Financial Perspectives first reported a position in STAB in Q4 2021 and held it in 4 quarters. The position peaked at $5.76K in Q4 2021. 29 funds tracked by Wall St. Rank hold STAB as of Q4 2022.

  • Financial Perspectives reported no remaining Statera Biopharma, Inc. Common Stock position as of Q4 2022 after selling out during the quarter.
  • Financial Perspectives sold 8,941 Statera Biopharma, Inc. Common Stock shares in Q4 2022, an estimated $1.16K.
  • Financial Perspectives first reported a position in Statera Biopharma, Inc. Common Stock in Q4 2021 and held it in 4 quarters.
  • Financial Perspectives's Statera Biopharma, Inc. Common Stock position peaked at $5.76K in Q4 2021.
  • 29 funds tracked by Wall St. Rank held Statera Biopharma, Inc. Common Stock as of Q4 2022.

Based on Financial Perspectives's 13F filing for Q4 2022, filed 10 Jan 2024.